Clinical Trial Will Evaluate Combination of Therapies in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas
Researchers Test Combination Therapy for Common Pediatric Tumors
A new clinical trial at Joseph M. Sanzari Children’s Hospital will evaluate possible treatment for recurrent low grade gliomas. While current therapies have demonstrated success in many patients with recurrent low grade gliomas, not all patients respond to single agent therapy, and many patients develop progression after completion of treatment.
During this trial, researchers will evaluate a potential combination therapy, Trametinib and Everolimus, to enhance effectiveness and prolong disease stabilization for patients with WHO Grade I-II gliomas. Low grade gliomas are among the most common pediatric tumors.
In the trial, a combination of the two medications will be administered in two dosing schedules. The first will evaluate a continuous dosing schedule, and the second, an intermittent dosing schedule. Researchers hope to validate evidence of potential effectiveness and patients’ ability to tolerate the medications.
Learn more about our advancements in pediatric oncology at Hackensack Meridian Children’s Health.